Breaking News Headlines Today | Ground News

See every side of every news story

Healio image

News from Healio

Healio’s media bias is Center. Ground News assigned this score by aggregating media bias ratings of a Center rating from Ad Fontes Media .

Healio’s factuality rating is Very High. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Healio

Where is Healio located?Healio's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byAd Fontes Media

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Healio News

New Menopause Drug to Target Hot Flashes without Hormones Gets FDA Approval

FDA · United States

New Menopause Drug to Target Hot Flashes without Hormones Gets FDA Approval

89% Center coverage: 46 sources

By Jacqueline Howard, CNN (CNN) — The US Food and Drug Administration has approved another once-a-day pill that works without hormones to treat moderate to severe hot flashes in menopausal women, drugmaker Bayer said Friday. The drug, elinzanetant, is expected to be available in the United States beginning in November under the brand name Lynkuet, Bayer said. It works by blocking the brain chemicals responsible for hot flashes and night sweats –…See the Story

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Eli Lilly · United States

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

69% Center coverage: 29 sources

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen See the Story

FDA Aims to Accelerate Biosimilar Development as Way to Reduce Drug Costs

Robert F. Kennedy Jr. · United States

FDA Aims to Accelerate Biosimilar Development as Way to Reduce Drug Costs

34% Center coverage: 3 sources

The FDA today unveiled a plan to accelerate development of biosimilars in hopes of significantly reducing drug costs in the United States.The agency issued draft guidance that would simplify the study of biosimilars and reduce what officials characterized as time-consuming, costly and unnecessary clinical testing.See the Story

Breaking News Topics Related to Healio